Major depressive disorder Mental and Behavioural Disorders Depressive episode
Conditions
Interventions
Please note that this is a non-interventional study
the objective is to evaluate in standard medical practice the safety of agomelatine prescribed to depressed patients.
Dosage: Agomelatine 25 mg tablets - according to the SmPC, 25 mg
Sponsors
Institut de Recherches Internationales Servier (France)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both genders patients aged at least 18 years or legal age of majority (without upper limit of age) 2. Initiated into agomelatine for their current depressive episode 3. Having signed an informed consent
Exclusion criteria
Exclusion criteria: 1. Having to stop an ongoing antidepressant with which they were treated with success for their depression 2. Already treated with another antidepressant that they wish to continue in addition to agomelatine 3. Planning to move during the 26 weeks of the follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of agomelatine prescribed to depressed patients, measured each time patients will come and visit his/her physician. Please note that participation of patients in the agomelatine cohort will not trigger additional medical follow-up visits. The participating physician will follow patients through control visits planned as part of normal clinical practice. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcome measures | — |
Countries
France, Germany, Italy, Netherlands, Portugal, Spain
Outcome results
None listed